ERBB2 and breast cancer: Therefore, it seemed consistent to regard a high level of HER2 amplification as a good predictive biomarker both for early HER2-positive breast cancer in the neoadjuvant treatment stage and HER2-positive MBC and as a prognostic biomarker for MBC.